| Title : Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia - Furze_2022_Br.J.Clin.Pharmacol__ |
| Author(s) :
Furze RC , Molnar J , Parr NJ , Ahmad F , Henry Y , Howe D , Singh R , Toal M , Bassil AK , Bernard SG , Davis RP , Gibson A , Maller NC , Sharp C , Tough DF , Prinjha RK , Lewis HD |
|
Ref :
British Journal of Clinical Pharmacology , : , 2022 |
| Abstract : Furze_2022_Br.J.Clin.Pharmacol__ |
| ESTHER : Furze_2022_Br.J.Clin.Pharmacol__ |
| PubMedSearch : Furze_2022_Br.J.Clin.Pharmacol__ |
| PubMedID: 35655123 |